Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin
Open Access
- 23 December 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (3) , 556-562
Abstract
Objective. To determine the safety and efficacy of prolonged treatment with 15-deoxyspergualin (DSG, gusperimus) in patients with relapsing WG. Methods. Patients with relapsing WG treated with DSG were studied. Other immunosuppressants except corticosteroids were withdrawn and DSG, 0.5 mg/kg/day, self-administered subcutaneously for up to 21 days, in 28-day cycles. The cycle was terminated early for white blood cell count 9/l. The prednisolone dose was adjusted according to the clinical state. End points were disease remission, relapse, Birmingham Vasculitis Activity Score (BVAS), prednisolone dose and safety. Results. Eleven patients, five (45%) of whom were female, received a total of 15 treatment periods with DSG. The median (range) duration of each treatment period was 6.8 (3.3–15.9) months. Ten (90.9%) patients responded in 13/15 courses after a median of 1.7 (0.7–2.7) months and six (54.5%) achieved remission after 7.7 (1.9–13.5) months. Two (18.2%) patients relapsed while continuing to receive DSG. Remission was maintained in other patients while DSG was continued. However, 7/8 relapsed after DSG withdrawal. The median BVAS fell from 10 (3–22) at baseline to 3 (0–16) at the end of each treatment period (P = 0.002). Median prednisolone doses were reduced from 20 (5–30) mg/day at baseline to 10 (5–25) mg/day at the end of each treatment period (P = 0.052). Three severe adverse events occurred in two patients. Conclusions. Extended treatment with DSG was effective in the majority of patients with relapsing WG and permitted prednisolone reduction. There was no unexpected toxicity associated with prolonged DSG administration.Keywords
This publication has 22 references indexed in Scilit:
- Deoxyspergualin in relapsing and refractory Wegener's granulomatosisAnnals of the Rheumatic Diseases, 2009
- Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated VasculitisAnnals of Internal Medicine, 2009
- EULAR recommendations for the management of primary small and medium vessel vasculitisAnnals of the Rheumatic Diseases, 2009
- Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patientsNephrology Dialysis Transplantation, 2005
- A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic AutoantibodiesNew England Journal of Medicine, 2003
- Outcome of ANCA-associated renal vasculitis: a 5-year retrospective studyAmerican Journal of Kidney Diseases, 2003
- 15-Deoxyspergualin in Patients with Refractory ANCA-Associated Systemic VasculitisJournal of the American Society of Nephrology, 2003
- Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener GranulomatosisAnnals of Internal Medicine, 1996
- Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide TherapyAnnals of Internal Medicine, 1993